Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Mineralys Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get MLYS alerts

About David Rodman

The proxy statement of Mineralys Therapeutics, Inc. reports total compensation of $2,204,704 for David Rodman in fiscal 2025, including a base salary of $533,000. Disclosed compensation is on record for 4 fiscal years. David Rodman has spoken on 4 earnings calls across 1 company, most recently for Mineralys Therapeutics, Inc. on November 10, 2025. Mineralys Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Mineralys Therapeutics, Inc. includes Jon Congleton (CEO and Board Member), Glenn P. Sblendorio (Chairman), Alexander Gold (Board Member) and 6 others.

David Rodman on recent calls

“We followed what we agreed upon with the FDA regarding the approach to handle missing data. As you know, figures exceeding 15% and especially 20% can cause significant issues, sometimes preventing the agency from evaluating those trials.”
CMO, Mineralys Therapeutics, Inc. Q3 FY2025 Earnings Call ·
“Picking up from where Jon just left off, discussing the KOL event we had last quarter, I agree that there were a lot of great topics discussed.”
CMO, Mineralys Therapeutics, Inc. Q4 FY2024 Earnings Call ·
“So the question, just to reiterate it and let me know if I've got it right, is are we going to encounter less confusion or less clarity, let's say at 12 weeks, because we have some people on 50 mg straight through and others who could have their dose increased to 100 mg?”
CMO, Mineralys Therapeutics, Inc. Q2 FY2024 Earnings Call ·
“The first inquiry was about the powering for the Advance trial, specifically regarding the placebo expectations. I want to remind you that in Advance, we're using 24-hour ambulatory blood pressure monitoring as the primary measure.”
CMO, Mineralys Therapeutics, Inc. Q1 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Mineralys Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Mineralys Therapeutics, Inc. (MLYS) $533,000 $2,204,704
2024 Mineralys Therapeutics, Inc. (MLYS) $520,000 $2,877,749
2023 Mineralys Therapeutics, Inc. (MLYS) $500,000 $2,334,207
2022 Mineralys Therapeutics, Inc. (MLYS) $411,458 $1,106,507

Recent activity